| chronic pain (diagnosis)

Prialt vs Belbuca

Side-by-side clinical, coverage, and cost comparison for chronic pain (diagnosis).

Deep comparison between: Prialt vs Belbuca with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsBelbuca has a higher rate of injection site reactions vs Prialt based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Belbuca but not Prialt, including UnitedHealthcare

Category

Prialt

Belbuca

At A Glance

RouteIntrathecal infusion

FrequencyContinuous infusion

ClassN-type calcium channel blocker

RouteBuccal film

FrequencyEvery 12 hours

ClassPartial opioid agonist

Indications

chronic pain (diagnosis)

chronic pain (diagnosis)

Dosing

chronic pain (diagnosis) Initiate at no more than 2.4 mcg/day (0.1 mcg/hr) intrathecally; titrate by up to 2.4 mcg/day at intervals no more than 2-3 times per week; maximum recommended dose 19.2 mcg/day (0.8 mcg/hr).

chronic pain (diagnosis) 75 mcg buccal film once daily or every 12 hours for opioid-naive patients, titrated in increments of 150 mcg every 12 hours no more frequently than every 4 days to a maximum of 900 mcg every 12 hours; initial dose for opioid-experienced patients: 150 mcg every 12 hours (30-89 mg oral MSE) or 300 mcg every 12 hours (90-160 mg oral MSE).

Contraindications

Known hypersensitivity to ziconotide or any formulation component
Any concomitant treatment or medical condition rendering intrathecal administration hazardous
Infection at the microinfusion injection site
Uncontrolled bleeding diathesis
Spinal canal obstruction that impairs circulation of CSF
Pre-existing history of psychosis

Significant respiratory depression
Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
Known or suspected gastrointestinal obstruction, including paralytic ileus
Hypersensitivity (e.g., anaphylaxis) to buprenorphine

Drug Interactions

478View drug interactions

890View drug interactions

Adverse Reactions

Most common (>=25%) dizziness, nausea, confusional state, nystagmus

Serious acute renal failure, atrial fibrillation, cerebrovascular accident, sepsis, meningitis, psychotic disorder, suicidal ideation, respiratory distress, rhabdomyolysis, fatal aspiration pneumonia, suicide attempt

Postmarketing hypersensitivity reactions including angioedema, bullous dermatitis, skin ulcers, skin exfoliation, burning skin sensation

Most common (>=5%) Nausea, constipation, headache, vomiting, fatigue, dizziness, somnolence

Serious Addiction, abuse, and misuse; life-threatening respiratory depression; interactions with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; QTc prolongation; hepatotoxicity; anaphylactic/allergic reactions; seizures

Postmarketing Serotonin syndrome, adrenal insufficiency, anaphylaxis, androgen deficiency, hyperalgesia and allodynia, dental decay (caries, tooth fracture, and tooth loss), hypoglycemia, opioid-induced esophageal dysfunction

Pharmacology

Ziconotide is an N-type calcium channel blocker; it binds to N-type calcium channels on primary nociceptive afferent nerves in the dorsal horn of the spinal cord, blocking excitatory neurotransmitter release from afferent nerve terminals and producing antinociception.

Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor; it produces analgesia by binding with high affinity to opioid receptors on neurons in the brain and spinal cord and, unlike full opioid agonists, exhibits a dose-ceiling effect on respiratory depression.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Prialt